Contemporary Issues in Lung CancerJones & Bartlett Publishers, 2009 M02 12 - 364 pages In the United States, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer death. Even more devastating is its five-year survival rate of only 15.8%. Despite these dismal facts, lung cancer receives little national attention and research and funding for lung cancer lags behind other cancers. The intent of Contemporary Issues in Lung Cancer: A Nursing Perspective Second Edition is to provide oncology nurses and healthcare professionals with in-depth information on the issues that surround this disease, so that they might impact both education and research and provide better care for their patients. |
From inside the book
Results 1-5 of 83
Page ix
Marilyn Haas. Preface. Being diagnosed with lung cancer is one of the greatest challenges men and women, along with their family members and friends, can ever face in their lifetimes. While there are more than 12 different kinds of lung ...
Marilyn Haas. Preface. Being diagnosed with lung cancer is one of the greatest challenges men and women, along with their family members and friends, can ever face in their lifetimes. While there are more than 12 different kinds of lung ...
Page 5
... diagnosis is 71 years of age (Reis, et al., 2007). There was no one under the age of 20 years diagnosed with the disease. The highest group was between 65 and 74 years of age (Table 1–2). Although the lung is the second most com- mon ...
... diagnosis is 71 years of age (Reis, et al., 2007). There was no one under the age of 20 years diagnosed with the disease. The highest group was between 65 and 74 years of age (Table 1–2). Although the lung is the second most com- mon ...
Page 6
Marilyn Haas. Age at Time of Lung Cancer Diagnosis/Death Table 1–4 Stage Distribution at Lung Cancer Diagnosis Time at. Source: SEER, data 2001–2005. Types of Lung Cancer Lung cancers arise from abnormal epithelial cells in the airways of ...
Marilyn Haas. Age at Time of Lung Cancer Diagnosis/Death Table 1–4 Stage Distribution at Lung Cancer Diagnosis Time at. Source: SEER, data 2001–2005. Types of Lung Cancer Lung cancers arise from abnormal epithelial cells in the airways of ...
Page 7
Marilyn Haas. Table 1–4 Stage Distribution at Lung Cancer Diagnosis Time at Diagnosis 5-Year Survival Rates Local 16% 49.5% Regional 25% 20.6% Distant 51% 2.8% Unknown 8% 8.3% (unstaged) Table 1–5 AJCC Staging of Lung Cancer Primary ...
Marilyn Haas. Table 1–4 Stage Distribution at Lung Cancer Diagnosis Time at Diagnosis 5-Year Survival Rates Local 16% 49.5% Regional 25% 20.6% Distant 51% 2.8% Unknown 8% 8.3% (unstaged) Table 1–5 AJCC Staging of Lung Cancer Primary ...
Page 8
... diagnosed after January 1, 2010. New anatomic markers and molecular or serum markers will be included in the staging and management strategies. In the proposed changes, there will be numerous changes in the T (tumor) descriptors, no ...
... diagnosed after January 1, 2010. New anatomic markers and molecular or serum markers will be included in the staging and management strategies. In the proposed changes, there will be numerous changes in the T (tumor) descriptors, no ...
Contents
Oncology Treatment Modalities | 45 |
Special Issues Facing Individuals with Lung Cancer | 117 |
Psychosocial Issues of Individuals with Lung Cancer | 231 |
Assistance and Resources for Individuals Facing Lung Cancer | 255 |
Media and Future Research Directions | 301 |
Index | 353 |
Other editions - View all
Common terms and phrases
adjuvant agents aprepitant associated bevacizumab breathing breathlessness Bruera carboplatin carcinoma cell lung cancer chemotherapy chronic cisplatin Clinical Oncology clinical trials combination diagnosis disease docetaxel dose drug dyspnea EGFR erlotinib etoposide evaluation evidence-based factors fatigue gefitinib gemcitabine gene improve increased individuals indoor radon Internet intervention irinotecan Journal of Clinical lung cancer patients Medicine ment metastatic months NCCN nicotine non-small cell lung NSCLC Nursing Forum Oncology Nursing Oncology Nursing Forum paclitaxel palliative palliative care patient navigation patients and families patients with lung pemetrexed phase potential pulmonary quit smoking radiation therapy radiotherapy radon randomized receptors regimen reported resection respiratory response rate risk role SCLC score screening Sekido side effects small cell lung smoking cessation stage strategies support group surgical survival rate Symptom Management Table tients tion tobacco topotecan toxicity treat treatment tumor versus vinorelbine weight loss